Future Search Trials
Welcome,         Profile    Billing    Logout  
 1 Trial 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Downing, Michael
REPOSA, NCT06146101: RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

Active, not recruiting
2/3
560
US
IHL-42X Low Dose, Phase 2 Investigational Product - IHL-42X Low dose, IHL-42X High Dose, Phase 2 Investigational Product - IHL-42X High dose, Placebo, Phase 2 Placebo, IHL-42X (Optimal Dose), Phase 3 Investigational Product - IHL-42X, Dronabinol, Phase 3 Comparator - Reference Listed Drug/Dronabinol, Acetazolamide, Phase 3 Comparator - Reference Listed Drug/Acetazolamide, Phase 3 Placebo
Incannex Healthcare Ltd
Obstructive Sleep Apnea
12/26
12/26
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

Recruiting
2/3
434
Europe, Japan, US
SEP-363856, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disorder
02/26
02/26
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1040
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
06/26
09/26
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
250
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
06/25
09/25
ENLIGHTEN, NCT05113771: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression

Completed
2
197
Canada, US
Liafensine, Placebo
Denovo Biopharma LLC
Treatment Resistant Depression
02/24
03/24
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management with LY3549492 Compared with Placebo in Adult Participants with Obesity or Overweight

Recruiting
2
275
US
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT05717439: Feasibility and ML Training Investigation of the Senseye DT for Diagnosis of Adults with PTSD

Completed
N/A
338
US
CAPS-5-R, Clinician-Administered Scale for PTSD for DSM-5, Revised version, Senseye DT
Senseye, Inc.
PTSD, Generalized Anxiety Disorder, Major Depressive Disorder
07/24
07/24
Bueno, Cassandra
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Downing, Michael
REPOSA, NCT06146101: RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

Active, not recruiting
2/3
560
US
IHL-42X Low Dose, Phase 2 Investigational Product - IHL-42X Low dose, IHL-42X High Dose, Phase 2 Investigational Product - IHL-42X High dose, Placebo, Phase 2 Placebo, IHL-42X (Optimal Dose), Phase 3 Investigational Product - IHL-42X, Dronabinol, Phase 3 Comparator - Reference Listed Drug/Dronabinol, Acetazolamide, Phase 3 Comparator - Reference Listed Drug/Acetazolamide, Phase 3 Placebo
Incannex Healthcare Ltd
Obstructive Sleep Apnea
12/26
12/26
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

Recruiting
2/3
434
Europe, Japan, US
SEP-363856, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disorder
02/26
02/26
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1040
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
06/26
09/26
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
250
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
06/25
09/25
ENLIGHTEN, NCT05113771: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression

Completed
2
197
Canada, US
Liafensine, Placebo
Denovo Biopharma LLC
Treatment Resistant Depression
02/24
03/24
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management with LY3549492 Compared with Placebo in Adult Participants with Obesity or Overweight

Recruiting
2
275
US
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT05717439: Feasibility and ML Training Investigation of the Senseye DT for Diagnosis of Adults with PTSD

Completed
N/A
338
US
CAPS-5-R, Clinician-Administered Scale for PTSD for DSM-5, Revised version, Senseye DT
Senseye, Inc.
PTSD, Generalized Anxiety Disorder, Major Depressive Disorder
07/24
07/24
Bueno, Cassandra
No trials found

Download Options